These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 26951040)

  • 1. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Bernstein MB; Krishnan S; Hodge JW; Chang JY
    Nat Rev Clin Oncol; 2016 Aug; 13(8):516-24. PubMed ID: 26951040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives.
    Rekers NH; Troost EG; Zegers CM; Germeraad WT; Dubois LJ; Lambin P
    Cancer Radiother; 2014 Oct; 18(5-6):391-5. PubMed ID: 25179250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy and radiotherapy for metastatic cancers.
    Bang A; Schoenfeld JD
    Ann Palliat Med; 2019 Jul; 8(3):312-325. PubMed ID: 30180743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?
    Walshaw RC; Honeychurch J; Illidge TM
    Br J Radiol; 2016 Oct; 89(1066):20160472. PubMed ID: 27556933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?
    Xing D; Siva S; Hanna GG
    Clin Oncol (R Coll Radiol); 2019 Jul; 31(7):432-443. PubMed ID: 31005381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The optimism surrounding stereotactic body radiation therapy and immunomodulation.
    Tharmalingam H; Hoskin PJ
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S9. PubMed ID: 28917247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.
    Blanchard M; Shim KG; Grams MP; Rajani K; Diaz RM; Furutani KM; Thompson J; Olivier KR; Park SS; Markovic SN; Pandha H; Melcher A; Harrington K; Zaidi S; Vile R
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):577-87. PubMed ID: 26461000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.
    Brooks ED; Schoenhals JE; Tang C; Micevic G; Gomez DR; Chang JY; Welsh JW
    Cancer J; 2016; 22(4):257-66. PubMed ID: 27441745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irradiation and immunotherapy: From concept to the clinic.
    Salama AK; Postow MA; Salama JK
    Cancer; 2016 Jun; 122(11):1659-71. PubMed ID: 26914620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
    Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
    Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines versus immunotherapy: overview of approaches in deciding between options.
    Dalgleish AG
    Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
    Hahn AW; Gill DM; Pal SK; Agarwal N
    Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination cancer immunotherapy and new immunomodulatory targets.
    Mahoney KM; Rennert PD; Freeman GJ
    Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
    Joshi M; Pal SK; Drabick JJ
    Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 1: Principles of Combined Treatment.
    Zhang I; Formenti SC; Knisely JPS
    Oncology (Williston Park); 2018 Feb; 32(2):e28-e32. PubMed ID: 29492951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
    Sweis RF; Luke JJ
    Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
    Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
    Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.